Cytokinetics, Incorporated CYTK
64.66
(1.00)
(1.52%)
as of 25 Sep
- Market cap
- $9.0B
- P/E
- 0.0×
Follow CYTK
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
281.08% | 197.47% | 151.81% | 329.76% | |
| (52.35%) | (55.55%) | (65.39%) | (56.76%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(82.52%) | (98.90%) | (114.79%) | (80.83%) | |
Average Days of Receivables |
7.57 | 73.65 | 23.55 | 131.78 | |
Free Cash Flow per Share |
(3.78) | (4.45) | (4.45) | (4.40) | |
Free Cash Flow |
(453.38) | (534.82) | (548.92) | (580.71) | |
Capital Expenditures |
(20.45) | (24.81) | (25.07) | (25.26) | |
Piotroski F-Score |
3.00 | 2.00 | 2.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(28.34%) | (36.96%) | (45.37%) | (25.96%) | |
Accounts Receivable Turnover |
85.00 | 5.12 | 23.94 | 4.12 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.43 | 0.66 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 1,073.54 | 616.70 | |
Days of Inventory on Hand |
— | — | 6.69 | 11.43 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
460.10% | 472.55% | 390.58% | 592.52% | |
Selling, General and Administrative Expense of Revenue |
292.26% | 322.89% | 313.56% | 547.47% | |
Share Based Compensation of Revenue |
123.87% | 127.54% | 112.58% | 188.13% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.58 | 0.65 | 0.63 | 0.62 | |
Depreciation/Fixed assets |
0.13 | 0.13 | 0.14 | 0.16 | |
Capex/Depreciation |
(2.12) | (2.45) | (2.24) | (2.01) | |
Revenue per Share |
0.73 | 0.73 | 0.86 | 0.51 | |
Operating CF per Share |
(3.61) | (4.25) | (4.25) | (4.21) | |
Capex per Share |
(0.17) | (0.21) | (0.20) | (0.19) | |
Capex to Sales |
0.23 | 0.28 | 0.24 | 0.37 | |
Net Profit Margin |
(862.21%) | (891.60%) | (784.02%) | (1,321.12%) |
Columns are period end dates